Jade Biosciences (JBIO) Net Cash Flow (2020 - 2026)

Jade Biosciences (JBIO) has 7 years of Net Cash Flow data on file, last reported at -$33.4 million in Q1 2026.

• Quarterly Net Cash Flow fell 404.99% year-over-year to -$33.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.7 million (down 104.7% YoY) and the FY2025 annual result came in at $19.1 million, up 85.79% from the prior year.
• Net Cash Flow declined to -$33.4 million in Q1 2026, from $38.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $158.2 million in Q2 2025 to a low of -$170.8 million in Q3 2025.
• A 5-year average of $6.9 million and a median of -$2.9 million in 2022 frame the typical range for Net Cash Flow.
• The widest YoY moves for Net Cash Flow: up 5133.72% in 2023, down 39395.45% in 2023.
• Tracing JBIO's Net Cash Flow over 5 years: stood at -$22000.0 in 2022, then plunged by 39395.45% to -$8.7 million in 2023, then jumped by 1049.65% to $82.5 million in 2024, then tumbled by 53.54% to $38.3 million in 2025, then tumbled by 187.03% to -$33.4 million in 2026.
• The last three Net Cash Flow figures came in at -$33.4 million (Q1 2026), $38.3 million (Q4 2025), and -$170.8 million (Q3 2025), per Business Quant data.